Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - AYTU BIOPHARMA, INC | aytu_8k.htm |
Exhibit
99.1
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business
Update
ENGLEWOOD, CO May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU)
(the "Company"), a specialty pharmaceutical company focused on
commercializing novel products that address significant patient
needs, announced today that the Company will present its
operational results for the quarter ended March 31, 2020 on May 14,
2020, at 4:30 p.m. ET. The Company will review accomplishments from
the quarter and provide an overview of its business and growth
strategy.
Conference Call Information
1- 877-407-9124 (toll-free)
1- 201-689-8584 (international)
The webcast will be accessible live and archived on Aytu
BioScience's website, within the Investors section under Events
& Presentations, at aytubio.com, for 90 days.
A replay of the call will be available for fourteen days. Access
the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331
(international) and using the replay access code
34718.
About Aytu BioScience, Inc.
Aytu BioScience, Inc. is a commercial-stage specialty
pharmaceutical company focused on commercializing novel products
that address significant patient needs. The Company currently
markets a portfolio of prescription products addressing large
primary care and pediatric markets. The primary care portfolio
includes (i) Natesto®, the only FDA-approved nasal formulation
of testosterone for men with hypogonadism (low testosterone, or
"Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray
prescription sleep aid, and (iii) Tuzistra® XR, the only
FDA-approved 12-hour codeine-based antitussive syrup. The pediatric
portfolio includes (i) AcipHex® Sprinkle™, a granule
formulation of rabeprazole sodium, a commonly prescribed proton
pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin
antibiotic suspension; (iii) Karbinal® ER, an extended-release
carbinoxamine (antihistamine) suspension indicated to treat
numerous allergic conditions; and (iv) Poly-Vi-Flor® and
Tri-Vi-Flor®, two complementary prescription fluoride-based
supplement product lines containing combinations of fluoride and
vitamins in various for infants and children with fluoride
deficiency. Aytu recently acquired exclusive U.S. distribution
rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is
a solid phase immunochromatographic assay used in the rapid,
qualitative and differential detection of IgG and IgM antibodies to
the 2019 Novel Coronavirus in human whole blood, serum or
plasma.
Aytu recently acquired Innovus Pharmaceuticals, a specialty
pharmaceutical company commercializing, licensing and developing
safe and effective consumer healthcare products designed to improve
men's and women's health and vitality. Innovus commercializes over
thirty-five consumer health products competing in large healthcare
categories including diabetes, men's health, sexual wellness and
respiratory health. The Innovus product portfolio is commercialized
through direct-to-consumer marketing channels utilizing the
Company's proprietary Beyond Human® marketing and sales
platform.
Aytu's strategy is to continue building its portfolio of
revenue-generating products, leveraging its focused commercial team
and expertise to build leading brands within large therapeutic
markets. For more information visit aytubio.com and visit
innovuspharma.com to learn about the Company's consumer healthcare
products.
Contact for Media and Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com